For research use only. Not for therapeutic Use.
Selinexor free base（Cat No.:I036199）is an oral, selective inhibitor of nuclear export (SINE) that targets the exportin 1 (XPO1) protein. By blocking XPO1, Selinexor disrupts the transport of tumor suppressor proteins and oncogenic mRNAs from the nucleus to the cytoplasm, leading to the reactivation of tumor-suppressing pathways and apoptosis in cancer cells. It is primarily used in the treatment of multiple myeloma and other hematologic malignancies. Selinexor’s unique mechanism provides a novel approach to cancer therapy, offering hope for patients with refractory or relapsed cancers.
| Catalog Number | I036199 |
| CAS Number | 1393477-72-9 |
| Synonyms | (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N’-pyrazin-2-ylprop-2-enehydrazide |
| Molecular Formula | C17H11F6N7O |
| Purity | 98% |
| Target | XPO1 |
| Target Protein | O14980 |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide |
| InChI | InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1- |
| InChIKey | DEVSOMFAQLZNKR-RJRFIUFISA-N |
| SMILES | C1=CN=C(C=N1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F |
| Reference | [1]. Etchin J, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013 Apr;161(1):117-27. [2]. Tai YT, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan;28(1):155-65. |
